Key result
Homozygous V142I transthyretin amyloidosis triggers fatal, refractory cardiogenic shock in complex congenital heart disease.
Why the study?
Homozygous p.(V142I)-ATTRv-CM presents earlier and progresses more aggressively than heterozygous forms, with diagnostic challenges when coexisting with complex congenital heart disease.
Case Report (n=1)
The rare coexistence of homozygous p.(V142I)-associated variant transthyretin amyloid cardiomyopathy and complex congenital heart disease highlights the aggressive clinical course of this TTR variant and underscores the diagnostic challenges when multiple cardiac pathologies intersect.
May warrant amyloid consideration in refractory shock with congenital disease; extends homozygous p.(V142I) spectrum but hypothesis-generating.
BACKGROUND: p.(V142I)-associated variant transthyretin amyloid cardiomyopathy (ATTRv-CM) is biologically aggressive and predominantly affects individuals of African ancestry. CASE SUMMARY: A 51-year-old Nigerian man was diagnosed with double outlet right ventricle by the adult congenital heart disease service, although challenging social circumstances hindered adherence to clinic appointments. He re-established regular contact after 3 years and underwent workup for corrective surgery. Cardiac amyloidosis was suspected on repeat echocardiogram and confirmed on cardiac magnetic resonance and bone scintigraphy. Genetic sequencing later identified homozygosity for the p.(V142I) transthyretin variant. He was referred for emergency transplant assessment after developing cardiogenic shock. Unfortunately, he died despite receiving supportive therapies. DISCUSSION: Homozygous p.(V142I)-ATTRv-CM presents earlier and advances more aggressively than its heterozygous counterpart. This unusual case highlights the diagnostic pitfalls when genetics, adult congenital heart disease, and advanced heart failure intersect. TAKE-HOME MESSAGE: In patients of African ancestry, a high index of suspicion for p.(V142I)-ATTRv-CM is needed to prompt early diagnosis and initiation of disease-modifying therapies.
No takes yet. Share an insight, caveat, or question.
Zathar et al. (2026) conducted a case report in p.(V142I)-associated variant transthyretin amyloid cardiomyopathy complicating double outlet right ventricle (n=1). Homozygous p.(V142I) transthyretin variant was evaluated. Homozygous p.(V142I)-associated variant transthyretin amyloid cardiomyopathy presented aggressively in a patient with complex congenital heart disease, leading to refractory cardiogenic shock and death.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: